Evidence map›Paper›PMID 41646090›Full record

ArticleESMO real world data and digital oncology2024

Challenges and opportunities for real-world evidence in clinical oncology-a view from the UK: proceedings of a national workshop.

M Craddock, C Dempsey, D Abdulwahid, J P C Baldwin, K Banfill, A Carver, A Chaturvedi, S Cheeseman, G W Cowell, M Daly and 22 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO real world data and digital oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

M CraddockRadiotherapy Related Research Group, Division of Cancer Sciences, School of Medical Sciences, University of Manchester, Manchester, UK.
C DempseyRadiotherapy Related Research Group, Division of Cancer Sciences, School of Medical Sciences, University of Manchester, Manchester, UK.
D AbdulwahidThe Christie NHS Foundation Trust, Manchester, UK.
J P C BaldwinLeeds Teaching Hospitals Trust, Leeds, UK.
K BanfillThe Christie NHS Foundation Trust, Manchester, UK.
A CarverUniversity Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
A ChaturvediThe Christie NHS Foundation Trust, Manchester, UK.
S CheesemanLeeds Teaching Hospitals Trust, Leeds, UK.
G W CowellQueen Elizabeth University Hospital, Glasgow and School of Cancer Sciences, University of Glasgow, Glasgow, UK.
M DalyRadiotherapy Related Research Group, Division of Cancer Sciences, School of Medical Sciences, University of Manchester, Manchester, UK.
A DekkerDepartment of Radiation Oncology (MAASTRO), GROW School for Oncology and Reproduction, Maastricht University Medical Centre, Maastricht, The Netherlands.
S R DubashMount Vernon Cancer Centre, London, UK.
S DuffieldNational Institute for Health and Care Excellence (NICE), London, UK.
I Fornacon-WoodRadiotherapy Related Research Group, Division of Cancer Sciences, School of Medical Sciences, University of Manchester, Manchester, UK.
M A C GarciaEdinburgh Cancer Centre, Edinburgh, UK.
P GoodleyDivision of Immunology, Immunity to Infection and Respiratory Medicine, University of Manchester, Manchester, UK.
H GreenRoyal Marsden NHS Foundation Trust, London, UK.
R J HolleyRadiotherapy Related Research Group, Division of Cancer Sciences, School of Medical Sciences, University of Manchester, Manchester, UK.
S IngramThe Christie NHS Foundation Trust, Manchester, UK.
S JonesThe Christie NHS Foundation Trust, Manchester, UK.
J KennedyProton Clinical Outcomes Unit, Proton Beam Therapy Centre, The Christie NHS Foundation Trust, Manchester, UK.
A LighternessThe Christie NHS Foundation Trust, Manchester, UK.
C K McGarryRadiotherapy Physics, Northern Ireland Cancer Centre, Belfast Health and Social Care Trust, Belfast, UK.
O McLaughlinPatrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK.
R MirMount Vernon Cancer Centre, London, UK.
B W PapiezBig Data Institute, University of Oxford, Oxford, UK.
D E J SnellingLeeds Teaching Hospitals Trust, Leeds, UK.
S TheophanousLeeds Teaching Hospitals Trust, Leeds, UK.
S WarrenNorthern Centre for Cancer Care Freeman Hospital, Newcastle upon Tyne, UK.
K ZuckerUniversity of Leeds, Leeds, UK.
G PriceRadiotherapy Related Research Group, Division of Cancer Sciences, School of Medical Sciences, University of Manchester, Manchester, UK.
C Faivre-FinnRadiotherapy Related Research Group, Division of Cancer Sciences, School of Medical Sciences, University of Manchester, Manchester, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Real-world data (RWD) are defined as information collected about patients as a routine part of treatment. To understand the status of RWD initiatives in oncology in the UK, an online survey and in-person workshop were conducted which aimed to characterise current perceptions of RWD, establish where real-world evidence (RWE) could support unmet clinical need, and to identify the barriers and solutions to obtaining this evidence. Self-selecting health care professionals including oncologists, physicists, radiographers, and health data researchers, as well as patient representatives, participated in an anonymous survey (

Indexed as

clinical trialsdata scienceevidence-based radiotherapypatient datareal-world data

Identifiers

PMID41646090
PMCPMC12836500

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.